简单的去回顾一下业务吧谢谢谢谢陈老师 下面我们做一个简单的回复先来看一下这一页图案我们本家其实是几家的然后通过这样的一个中心驱动战略的引领下我们其实是建立了一个所谓创新二家英美的中心驱动战略我们创新二和英美战略的方向是进行转型和升级那么成绩成功的达到通过年轻人年轻的生物治疗企业的那我们看到 可以看到目前主要是三大优越版的创新以及创新200块那我们的英语平台美颜空间的话会通过生理版本的教授分析在二三年实现生物平台生产性200我们改造了一个全新的一代新型的英语平台通过全球化的布局和百分百的生存新专业的 不好意思嘉莉总我这边听有一点模糊您看能不能换一个接触方式我这边刚听一直比较模糊对对对看看您是不是用一下换个耳机或者说是我们这个就公放一下刚刚确实有点模糊这样可以吗 那我们英美这边的话呢其实是通过3.0版本的销售升级在23年实现了4.21的收入同比上升了200%我们是成功的打 打造一个全新的一站式清醒的英美平台然后通过这个全球化的布局本地化的生产以及这个全面专业的英美产品举证以及我们的产品研发和推进能力和多元化的营销的一个能力以制造企业的严谨创新来打造这个中国英美全产品举证的这样子的一个英美企业的 那我们在年内的话呢 ...

Product Approvals and Market Penetration - Four new non-PVC dual-chamber bag products were included in the 2023 National Medical Insurance Catalogue, which is expected to enhance patient usage willingness and accelerate market penetration in China [14]. - The proton pump inhibitor innovative drug Anjowei® (sodium anaprazole enteric-coated tablets) developed by Xuan Bamboo Biotechnology Co., Ltd. was also included in the 2023 National Medical Insurance Catalogue, facilitating faster hospital access and positive impact on company performance [14]. - Insulin aspart injection, insulin aspart 30 injection, and insulin aspart 50 injection developed by Huisheng Biopharmaceutical Co., Ltd. received drug registration approval from the National Medical Products Administration, marking the first approved insulin (analog) product to meet various clinical needs of diabetes patients [14]. - In November 2023, Sihuan Pharmaceutical's Azithromycin for Suspension and Dopamine Hydrochloride Injection won the bid for the ninth batch of national centralized procurement, which will enhance market share for these products [19]. - In December 2023, Xuanzhu Biopharm's Anaprazole Sodium Enteric-coated Tablets were included in the National Reimbursement Drug List, expected to lead to rapid sales growth and positively impact company performance [17]. - In December 2023, Huisheng Biopharm's Insulin Aspart Injection products received New Drug Application approval, addressing diverse clinical needs for diabetic patients [18]. - The inclusion of four non-PVC solid-liquid dual chamber bag products in the National Reimbursement Drug List in December 2023 is expected to increase market penetration and sales [16]. - Xuanzhu Biopharm's Anaprazole Sodium is recognized as the first and only PPI fully developed in China, highlighting the company's innovative capabilities [29]. - The NDA for Birociclib, a Class 1 new drug, was presented at the ASCO Annual Meeting in June 2023, showing potential efficacy in HR+ breast cancer patients resistant to endocrine therapy [33]. - The NDA for insulin degludec injection and Janagliflozin has been accepted by NMPA [53]. - The NDA for Anaprazole Sodium Enteric Dissolve Tablets has been accepted by the NMPA [54]. Clinical Trials and Research Developments - Xuanzhu Biopharm's Birociclib monotherapy for HR+/HER2- advanced breast cancer was accepted by the NMPA in October 2023, marking a significant advancement in treatment options for this patient group [20]. - The phase II clinical trial results of Birociclib demonstrated significant statistical differences compared to the control group, indicating its potential effectiveness in treating advanced breast cancer [26]. - In October 2023, Huisheng Biopharm's Insulin Degludec and Liraglutide Injection received approval to initiate clinical studies for type 2 diabetes, enhancing the company's product pipeline [25]. - The phase II clinical trial for Anaprazole Sodium Enteric-coated Tablets, developed by Xuanzhu Biopharm, completed patient enrollment in April 2023, targeting reflux esophagitis treatment [36]. - The completion of the phase III clinical trial for Birociclib in combination with fulvestrant reached its primary endpoint, indicating progress in advanced breast cancer treatment [36]. - The GLP-1 receptor agonist Semaglutide Injection is currently in clinical phase III for glucose-lowering indication, with weight-loss indication expected to file for IND in the second half of 2024 [151]. - Clinical research for Pyrotinib in HR+/HER2- advanced breast cancer has been accepted for NDA submission, with results recognized at major oncology conferences [179]. Financial Performance and Market Strategy - The Group recorded total revenue of approximately RMB1,860.5 million, a year-on-year decrease of approximately 14.7% compared to RMB2,181.2 million in the same period of 2022 [196]. - The medical aesthetics segment achieved revenue of approximately RMB449.9 million, representing a year-on-year increase of approximately 200.3% due to the easing of pandemic controls and recovery of consumer demand [197]. - The generic medicine segment reported revenue of approximately RMB1,398.8 million, a year-on-year decrease of approximately 29.0% due to price reductions from centralized procurement and declines in sales volumes [198]. - Revenue from innovative drugs and other drugs was approximately RMB11.8 million, reflecting a year-on-year decrease of 80.6% primarily due to the divestment of certain API companies [199]. - The Group invested approximately RMB577.7 million in R&D, a year-on-year decrease of 38.3%, as several products completed phase III clinical trials [200]. - The Group's pharmaceutical business achieved phased results with one innovative drug and three biopharmaceutical products receiving NDA approvals during the year [170]. - The Group is developing a pipeline of over 100 medical aesthetics and biopharmaceutical products, aiming to accelerate product industrialization and value amplification [200]. Awards and Recognition - Sihuan Pharmaceutical was recognized as one of the "2023 Top 100 Chinese Pharmaceutical Innovative Enterprises," highlighting its competitive advantages in the innovative drug field [88]. - Sihuan Pharmaceutical won the "Transformation Pioneer Enterprise of the Year 2023" award for its innovative business strategy, focusing on medical aesthetics and innovative drugs [90]. - The company received the "Best Innovation Value Award of the Year" for its innovative business strategies, showcasing its achievements in innovation [94]. - Sihuan Pharmaceutical was awarded the "Most Valuable Pharmaceutical and Medical Company," reflecting its strong corporate governance and stable value return for investors [97]. - The Chief Financial Officer, Ms. Miao Guili, was recognized as the "Best CFO," emphasizing the company's financial leadership [97]. - Sihuan Pharmaceutical won the "Best ESG Award," indicating its commitment to environmental, social, and governance performance [100]. - The company was also awarded the "ESG Pioneer Enterprise Award" at the 2023 ESG Summit, recognizing its efforts in ESG system construction and information disclosure [103]. - Xuanzhu Biopharm was recognized as one of the "Top 10 Most Growing Enterprises of Small Molecule Innovative Drugs" at the 2023 China Biomedical Technology Innovation Value List ceremony [113]. - Xuanzhu Biopharm was also rated as one of the "2023 China Top 100 Companies with Comprehensive Drug R&D Ability" based on extensive analysis of R&D-related data [116]. - Xuanzhu Biopharm received the title of "Top 50 Scientific and Innovative Leaders of China's Pharmaceutical Enterprises in 2023" for its outstanding R&D capabilities [120]. - Xuanzhu Biopharm was included in the "Forbes China Unicorn Enterprises" list, highlighting its innovation-driven approach and core proprietary intellectual property [123]. Strategic Focus and Future Plans - The Group intends to divest and dispose of some generic drugs and non-core pharmaceutical or healthcare businesses to focus on medical aesthetics and biopharmaceuticals, enhancing resource allocation efficiency [47]. - The company aims to transform towards medical aesthetics and innovative drugs, capitalizing on the growing market demand in the post-pandemic era [140]. - The light medical aesthetics industry in China is expected to experience explosive growth in 2024, transitioning from a luxury market to a mass consumer market [143]. - The company aims to enhance its global competitiveness while focusing on unmet clinical needs and developing innovative drugs [123]. - The company plans to expedite the NDA of innovative drugs and achieve product iteration of generic drugs through innovative drugs [155]. - The Group's strategic focus on registration, production, and sales capabilities is designed to create a solid competitive advantage in the pharmaceutical market [192]. - The Group is divesting non-core pharmaceutical and healthcare assets to focus on innovative drug development, aligning with its long-term strategic goals [191].

Financial Performance - The total revenue for the year was approximately RMB 1,860.5 million, a decrease of about 14.7% compared to RMB 2,181.2 million in the previous year[2]. - Revenue from generic drug sales was approximately RMB 1,398.8 million, down 29.0% from RMB 1,970.5 million, primarily due to price reductions and volume declines[3]. - Gross profit for the year was approximately RMB 1,295.6 million, a decrease of 12.9% from RMB 1,487.6 million, with a gross margin of 69.6%, up from 68.2%[3]. - Operating profit for the year was approximately RMB 161.7 million, a significant improvement from an operating loss of RMB 1,830.7 million in the previous year[3]. - The net loss for the year was approximately RMB 257.7 million, a reduction from RMB 2,283.3 million in the previous year[4]. - Cash flow from operating activities was approximately RMB 199.5 million, with cash and cash equivalents totaling approximately RMB 4,610.5 million as of December 31, 2023[4]. - Financial expenses increased by 27.5% to approximately RMB 269.3 million, primarily due to interest expenses related to redeemable liabilities[3]. - The company’s loss attributable to owners was approximately RMB 54.0 million, a decrease of 97.2% from RMB 1,914.9 million in the previous year[4]. Research and Development - Research and development expenses were approximately RMB 577.7 million, down 38.3% from RMB 936.6 million, due to the completion of several clinical trials[3]. - The company has made significant progress in the research and development of innovative drugs, with multiple self-developed products achieving substantial advancements[11]. - The innovative drug Anaprazole Sodium Enteric-Coated Tablets received approval from the National Medical Products Administration in June 2023 and was included in the National Medical Insurance Catalog[11]. - The company has submitted NDA applications for two indications of Pyrotinib, which have been accepted, and the clinical research results were presented at major oncology conferences[12]. - The company has advanced three globally leading innovative drugs into clinical stages, including XZP-KM501, XZP-6877, and XZP-KM602, with the latter receiving FDA approval for clinical trials in September 2023[12]. Market and Business Strategy - The management noted a significant slowdown in the Chinese consumer market, impacting the medical beauty sector and indicating a shift in consumer behavior[5]. - The company is committed to a dual-driven strategy of "innovative drugs + medical aesthetics," which has proven effective in enhancing its market position[8]. - The ongoing medical reform in China continues to drive the pharmaceutical industry, despite challenges such as volume-based procurement and economic downturns[7]. - The company is gradually divesting non-core pharmaceutical and health-related businesses to focus on innovative drug development[14]. - The company aims to improve cash flow generation capabilities while adhering to the dual-driven strategy of "medical aesthetics + innovative drugs" to maximize shareholder value[58]. Medical Aesthetics Segment - The medical aesthetics segment saw a substantial recovery in sales revenue, driven by the successful upgrade of the 3.0 version of the sales platform, resulting in a significant increase in sales[9]. - The medical aesthetics platform, Meiyan Space, expanded its sales channels to cover a total of 4,700 medical beauty institutions across the country, achieving 100% coverage of the top 500 institutions[9]. - The company has launched multiple products in the medical aesthetics sector, including Botulinum Toxin and Hyaluronic Acid, which have received positive recognition from consumers and medical institutions[10]. - The aesthetic medicine segment achieved revenue of approximately RMB 449.9 million, a significant increase of about 200.3% due to the lifting of pandemic restrictions and recovery in consumer demand[16]. - The company aims to build a leading position in the Chinese aesthetic medicine market through a robust product matrix and diverse marketing channels[20]. Awards and Recognition - The company has been recognized with several awards, including the "Outstanding Enterprise Award" at the 2023 China Medical Beauty Industry Awards and the "Annual Botulinum Toxin Brand Award" at the 3rd Light Chasing Awards[10]. - The company has been recognized with multiple awards, including "Forbes China's Unicorn Enterprise" and "Top 10 Most Growth-Oriented Small Molecule Innovative Drug Enterprises" in 2023[12]. Financial Position and Liabilities - The group maintained a stable financial position with cash and cash equivalents totaling approximately RMB 4,610.5 million as of December 31, 2023, after deducting interest-bearing bank loans[18]. - The group's borrowings to equity ratio was 25.6%, indicating a moderate level of leverage[18]. - The total liabilities increased to RMB 4,106,802 thousand from RMB 2,533,000 thousand in the previous year[62]. - The company reported a total impairment loss on non-current assets was RMB (1,291,043) thousand, with significant losses attributed to innovative drugs and other pharmaceuticals[78]. Operational Efficiency - The company has implemented a comprehensive operational transformation, integrating sales, planning, production, and logistics through an online ERP expansion module[49]. - The company has enhanced its production capacity to over 10 million units and improved internal operational efficiency and R&D effectiveness through production line upgrades[49]. - The company is focusing on optimizing its generic drug business while accelerating the divestiture of non-core traditional pharmaceutical assets[51]. Future Outlook - The company aims to achieve better performance in 2024 through a dual model of direct sales and agency management for its new product line, Meiyan Space[34]. - The company is actively pursuing market expansion and new strategies in drug development and commercialization[37]. - The company aims to expand its product portfolio with innovative therapies targeting cardiovascular and chronic kidney diseases[45].

Financial Performance - Sihuan Pharmaceutical reported a strong interim performance with a revenue increase of 15% year-on-year, reaching HKD 1.2 billion[5]. - The company achieved a net profit of HKD 300 million, representing a 20% increase compared to the same period last year[5]. - The management provided an optimistic outlook, projecting a revenue growth of 20% for the full year 2023[5]. - The Group recorded total revenue of approximately RMB1,055.7 million, representing a year-on-year decrease of approximately 27.9% compared to RMB1,464.2 million in the same period of 2022[25]. - The loss before tax for the Period was approximately RMB33.1 million, a decrease of RMB89.1 million from the profit of RMB56.0 million in the same period of 2022[28]. - The loss attributable to owners of the Company amounted to approximately RMB49.6 million, representing a year-on-year decrease of 222.8% in profit[29]. - The Group's loss for the Period amounted to approximately RMB118.9 million, representing a year-on-year increase of 24.0%[99]. Market Expansion and Strategy - Sihuan Pharmaceutical is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[5]. - The company plans to launch three new products in the next quarter, focusing on innovative biopharmaceutical solutions[5]. - The Group's strategic goal is to become a leading medical aesthetic and biopharmaceutical company in China, supported by its innovative platforms[12]. - The Group aims to implement a "Innovative Pharmaceuticals + Medical Aesthetics" dual-wheel drive strategy to enhance resource utilization efficiency and improve overall profit structure[92]. Research and Development - The company has allocated HKD 200 million for R&D in the upcoming year to enhance its product pipeline[5]. - Domestic Biopharma R&D investment continues to grow rapidly, with the R&D expense rate approaching the level of some multinational corporations (MNCs)[9]. - The Group has over 40 medical aesthetic products and more than 30 innovative biopharmaceutical products in its pipeline, enhancing its core competencies in registration, production, and sales[22]. - The Group's innovative drug platform is focused on critical illness areas, including digestion, oncology, and non-alcoholic steatohepatitis (NASH), aiming to develop class 1 innovative drugs with core independent intellectual property rights[48]. Product Development and Approvals - Xuanzhu Biopharm received approval to initiate clinical trials for XZP-KM501, marking its first antibody-drug conjugate entering clinical development[13]. - The approval of clinical trials for XZP-KM602 and XZP-6877 tablets indicates the Group's ongoing efforts in advancing treatments for advanced solid tumors[13]. - The NDA for Insulin Degludec and Insulin Aspart Injection developed by Huisheng Biopharm was accepted by the NMPA, marking it as the first biosimilar of its kind in China[15]. - The commercialization plan for Anaprazole Sodium has been systematically developed, focusing on marketing organization, team building, and sales forecasting[62]. Financial Health and Cash Flow - As of June 30, 2023, the Group's cash and cash equivalents plus wealth management products amounted to approximately RMB4,510.0 million, with cash and cash equivalents at RMB3,734.0 million[32]. - The Group maintained a net cash inflow of RMB28.3 million in operating cash flow during the period[32]. - The banking borrowings to equity ratio was 28.9%, indicating a low level of debt relative to equity[32]. - The net cash flows from operating activities amounted to approximately RMB28.3 million during the Period[100]. Medical Aesthetics Segment - The medical aesthetics segment achieved revenue of approximately RMB194.0 million, a year-on-year increase of approximately 96.8%, with a gross profit of approximately RMB135.2 million, up 76.0% year-on-year[25]. - The medical aesthetics platform Meiyan Space has successfully upgraded to version 3.0, significantly increasing sales revenue and covering 337 cities and over 4,000 medical aesthetics institutions by August 15, 2023[19]. - Meiyan Space launched the exclusive Hyaluronic acid PersnicaTM product from South Korea's Hugel, forming a "golden combination" with Letybo® botulinum toxin, gaining early recognition from medical aesthetics institutions and consumers[19]. - The medical aesthetics business segment is becoming a new growth driver for the Group, contributing to revenue growth alongside traditional segments[33]. Corporate Governance and Shareholding - The Company has complied with all applicable code provisions as set out in the Corporate Governance Code throughout the Period[151]. - The Company has a significant concentration of ownership, with major shareholders holding over 55% of the total shares[123]. - The total number of Shares held by major shareholders with 5% or more interest includes Mr. Meng Xianhui with 5,133,125,704 Shares, also representing 55.02%[123]. - The Company has adopted share option and share award schemes to recognize and reward employee contributions[112]. Challenges and Industry Trends - The overall profitability of the pharmaceutical industry began to stabilize, with the impact of centralized procurement policies on traditional pharmaceutical companies bottoming out[8]. - The pharmaceutical manufacturing industry is gradually recovering as the impact of the epidemic dissipates and medical reimbursement cost-control policies mature[10]. - The emphasis on research and development of drugs with clinical value and patient benefits is becoming a core focus for pharmaceutical enterprises[8]. - The innovative transformation development is recognized as a necessary path for pharmaceutical enterprises to maintain a favorable development trend[8].

Financial Performance - The revenue for the six months ended June 30, 2023, was approximately RMB 1,055.7 million, a decrease of 27.9% compared to RMB 1,464.2 million for the same period in 2022[2]. - The gross profit for the same period was approximately RMB 747.7 million, down 25.5% from RMB 1,003.7 million in the previous year[2]. - The operating profit for the period was approximately RMB 146.2 million, down 28.1% from RMB 203.2 million for the same period in 2022[3]. - The loss for the period was approximately RMB 118.9 million, compared to a loss of RMB 95.9 million in the previous year[3]. - The company reported a loss attributable to shareholders of approximately RMB 49.6 million, a decline of 222.8% year-on-year[15]. - The company reported a pre-tax loss of RMB 33,054 thousand for the six months ended June 30, 2023, compared to a pre-tax profit of RMB 56,042 thousand for the same period in 2022[60]. - The company reported a basic loss per share of RMB 0.53 for the six months ended June 30, 2023, compared to earnings of RMB 0.43 per share in the same period of 2022[47]. Business Segments - The aesthetic medicine business revenue and segment operating profit were approximately RMB 194.0 million and RMB 62.9 million, respectively, representing year-on-year increases of 96.8% and 51.2%[2]. - The revenue and segment operating profit for the generic drug business were approximately RMB 845.7 million and RMB 356.7 million, respectively, reflecting declines of 31.4% and 47.8% year-on-year[3]. - The innovative drugs and other pharmaceuticals segment generated revenue of approximately RMB 16.0 million, a year-on-year decrease of 87.9%, resulting in a segment loss of approximately RMB 344.0 million[14]. - The medical beauty segment achieved revenue of approximately RMB 194.0 million, a year-on-year increase of about 96.8%, with a gross profit of approximately RMB 135.2 million, up 76.0% year-on-year[14]. Research and Development - Research and development (R&D) expenses for the period were approximately RMB 294.0 million, a decrease of 35.7% from RMB 457.3 million in the same period last year[3]. - The R&D expenditure for the innovative drug and other business segments was RMB 214.2 million, a decrease of 32.5% compared to RMB 317.5 million in the same period last year[25]. - The company has over 25 innovative drugs in development, focusing on breast cancer and other therapeutic areas such as tumors, NASH, and digestive diseases[28]. - The innovative drug pipeline is well-balanced across various stages, ensuring continuous innovation and development[28]. Cash Flow and Financial Position - Cash and cash equivalents as of June 30, 2023, were approximately RMB 3,734.0 million, with additional financial products totaling approximately RMB 776.0 million[3]. - The company reported a net cash flow from operating activities of approximately RMB 28.3 million, with a year-end dividend payment of approximately RMB 298.6 million to shareholders[118]. - The company’s total cash and cash equivalents at the beginning of the period were RMB 3,828,863 thousand, compared to RMB 5,682,425 thousand at the start of the previous year[53]. - The company’s bank borrowings increased to RMB 1,273,430 thousand from RMB 1,135,458 thousand, an increase of approximately 12.2%[49]. Market and Strategic Developments - The company plans to accelerate the commercialization of new innovative drugs as the domestic new drug review and approval process speeds up[5]. - The pharmaceutical industry is expected to recover gradually as the impact of the pandemic diminishes and medical insurance cost control policies mature[5]. - The group is advancing its strategy of dual-driven innovation in pharmaceuticals and medical aesthetics, aiming to become a leading player in the Chinese market[6]. - The company is focusing on expanding its medical beauty product offerings, which have shown resilience despite overall revenue declines[59]. Product Development and Approvals - The group’s subsidiary Xuan Zhu Biotechnology received approval for clinical trials of its first antibody-drug conjugate (ADC) for HER2-positive solid tumors[8]. - The group’s subsidiary Huisheng Biotechnology's application for the dual insulin injection has been accepted by the National Medical Products Administration, marking a significant milestone in its product development[9]. - The company has received approval for three generic drugs related to diabetes complications, marking a significant step into commercialization[34]. - The company aims to cover the entire diabetes and complications treatment spectrum through a comprehensive product pipeline[35]. Operational Efficiency and Cost Management - Administrative expenses decreased by 33.7% year-on-year to approximately RMB 212.2 million, due to cost-cutting measures implemented by the company[110]. - Financial expenses increased by 34.3% year-on-year to approximately RMB 133.5 million, primarily due to interest costs related to share repurchase liabilities from equity financing[113]. - The company is committed to implementing a dual-driven strategy of "Innovative Drugs + Medical Aesthetics" to improve resource allocation efficiency and long-term financial performance[45]. Employee and Shareholder Engagement - The group employed 3,241 employees as of June 30, 2023[135]. - The company has a stock option plan that allows for the issuance of up to 10% of the issued shares at any time, with a maximum of 30% of unexercised options available for issuance[88]. - The company recorded a total expense of RMB 788,000 related to the stock option plan for the six months ending June 30, 2023, compared to RMB 6,187,000 for the same period in 2022[93].

Impairment Losses - The total impairment loss for the year ended December 31, 2022, amounted to RMB 1,727,119,000[1]. - The impairment losses by business segment include RMB 976,588,000 for the generic drugs segment, RMB 314,455,000 for innovative drugs and other products, and RMB 436,076,000 for unallocated amounts[2]. - The impairment in the generic drugs segment was primarily due to the impact of centralized procurement policies and the inclusion of more products in the key drug monitoring catalog[2]. - The company recognized an impairment loss of RMB 3,912,000 related to certain ongoing product development projects that were deemed to have low future returns[3]. - The impairment review and valuation were based on cash flow forecasts approved by management, reflecting specific risks associated with the business[4]. - The company conducts annual asset impairment assessments and will perform more frequent evaluations if events indicate potential impairments[2]. Centralized Procurement Policies - Management adjusted revenue and gross margin forecasts due to the ongoing implementation of centralized procurement policies affecting multiple cash-generating units[5]. - The anticipated full implementation of the seventh batch of centralized procurement policies is expected to have immediate pricing impacts on generic drug products[5]. - The company noted that the inclusion of products in the key drug monitoring catalog negatively affects sales volumes, particularly for generic and raw materials drugs[5]. - Supply chain disruptions and rising raw material and transportation costs due to the pandemic have significantly impacted the cash-generating units in the generic and raw materials drug segments[5].

Business Strategy and Focus - Sihuan Pharmaceutical reported a significant focus on high-growth therapeutic areas including medical aesthetics, oncology, metabolism, diabetes, and cardiovascular diseases[4]. - The company aims to build a leading position in the medical aesthetics and biopharmaceutical sectors in China through its two-wheeled strategy[4]. - The company has a strategic goal of advancing its medical aesthetics and biopharmaceuticals simultaneously, reflecting a dual focus on growth[4]. - The Group intends to divest and dispose of some generic drugs and non-core pharmaceutical businesses to focus on medical aesthetics and biopharmaceuticals, enhancing resource allocation efficiency[17]. - The Group aims to optimize and integrate its generic drug business while gradually spinning off underperforming segments to focus on high-growth medical aesthetics and innovative drugs[103]. - The Group's strategic focus is on the medical aesthetic and biopharmaceutical sectors, optimizing resource allocation to enhance long-term financial performance[127][128]. Innovation and R&D - Sihuan Pharmaceutical emphasizes innovation-driven growth, supported by its independent R&D technology platform[4]. - Sihuan Pharmaceutical's commitment to innovation is evident in its extensive R&D efforts across various therapeutic areas[4]. - The Group's innovative drug platform has seen a significant increase in corporate value and financing capacity due to enhanced R&D capabilities and product pipelines[159]. - The Group's R&D expenditure for the year was approximately RMB936.6 million, an increase of RMB68.5 million compared to RMB868.1 million in the previous year[151]. - Xuanzhu Biopharm has over 25 products in its pipeline, focusing on innovative drug development for breast cancer[92]. - The company has nearly 10 products approved for clinical trials and over 10 drug candidates in preclinical development, indicating a balanced and complete pipeline[138]. Financial Performance - In 2022, the revenue of the company was RMB 2,181,189, a decrease of 28.4% compared to RMB 3,038,391 in 2021[85]. - The gross profit for 2022 was RMB 1,487,581, resulting in a gross profit margin of 68.2%, down from 80.0% in 2021[85]. - Operating loss for 2022 was RMB 1,830,727, compared to an operating profit of RMB 771,945 in 2021[85]. - The loss before tax from continuing operations for the year was approximately RMB2,122.8 million, a shift from a profit of RMB496.0 million in 2021, including non-cash impairment losses of approximately RMB1,727.1 million[160]. - The medical aesthetic business segment generated revenue of RMB149.8 million, representing a year-on-year decrease of 62.5%, with an operating profit of RMB3.6 million[167]. Market Position and Expansion - Sihuan Pharmaceutical has developed a rich global product pipeline and a mature sales system, enhancing its competitive edge in the market[4]. - The company is positioned to capitalize on the growing demand in the medical aesthetics and biopharmaceutical markets, aiming for sustained growth[4]. - The Group's organizational restructuring aims to focus on high-growth segments, enhancing operational efficiency and maximizing shareholder value[124]. - The relaxation of epidemic control measures in early 2023 is expected to drive a V-shaped rebound in the medical aesthetics industry, leading to strong corporate performance recovery[116]. - The medical aesthetics market is projected to recover rapidly in 2023, benefiting from pent-up demand as economic activities resume[116]. Product Development and Approvals - The modified sodium hyaluronate gel for injection (PersnicaTM) received Class III medical device registration, enriching the product matrix and enabling rapid market penetration in the hyaluronic acid filler market[17]. - A total of 20 self-developed products received medical device registration, focusing on wound healing and scar repair, further expanding the medical beauty product portfolio[19]. - The IND application for KM501, a bispecific antibody drug conjugate, has been accepted by the NMPA, further expanding the company's innovative drug portfolio[138]. - The NDA for the fourth generation insulin degludec injection developed by Huisheng Biopharm has been accepted by the NMPA, being the first domestic analogue to achieve this milestone[23]. - Xuanzhu Biopharm's key product, Pyrotinib, has completed enrollment for Phase III clinical trials for breast cancer treatment, with nearly 10 products approved for clinical trials[136]. Strategic Partnerships and Collaborations - MeiYan KongJian signed an exclusive distribution agreement for CELLBOOSTER® series products, obtaining rights in mainland China, Hong Kong, Macau, and Taiwan, demonstrating commitment to the medical aesthetics sector[19]. - A joint venture with Bluepha will focus on developing PHA microspheres and bio-manufacturing-based regenerative medical materials, enhancing the Group's competitiveness in synthetic biology[19]. - Xuanzhu Biopharm has reached an exclusive licensing agreement with Shanghai SPH New Asia Pharmaceutical for two new anti-infection drugs in the Greater China Region[21]. - Xuanzhu Biopharm and WuXi XDC announced a collaboration for the development and manufacturing of the innovative oncology drug KM501, a bispecific antibody drug conjugate[29]. Awards and Recognition - Xuanzhu Biopharm was ranked among the "Top 10 Innovative Biopharmaceutical Companies" in the "Future Healthcare VB 100," showcasing its recognition in the innovative healthcare sector[74]. - Xuanzhu Biopharm was awarded the title of "Beijing Technologically Advanced Small- and Medium-sized Enterprises," highlighting its innovation capability and expertise[76]. - Huisheng Biopharm was awarded the title of "National Intellectual Property Advantage Enterprise" in 2022, reflecting high recognition from the government and market for its intellectual property efforts[84][85]. - The Group received the "Annual Transformation Pioneer Company Award" in recognition of its successful strategic transformation and market positioning[121]. Challenges and Market Conditions - In 2022, the domestic medical aesthetic industry faced challenges due to repeated epidemics, leading to suppressed demand and lower-than-expected product sales[94]. - The pharmaceutical industry experienced a volatile performance in 2022, with profit margins squeezed by centralized procurement price reductions[120]. - The medical aesthetics industry faced challenges in 2022 due to COVID-19 lockdowns, leading to suppressed consumer demand and lower product supply than initially expected[116].

Financial Performance - The group's revenue from continuing operations for the year was approximately RMB 2,181.2 million, a decrease of 28.2% compared to RMB 3,038.4 million for the previous year[2]. - Gross profit from continuing operations was approximately RMB 1,487.6 million, down 38.8% from RMB 2,430.5 million in the previous year[3]. - The company reported a net loss of approximately RMB 2,283.3 million for the year, compared to a profit of RMB 232.8 million in the previous year[4]. - Basic loss per share for the year was RMB 20.52[5]. - The group reported an impairment loss of approximately RMB 1,727.1 million due to policy changes affecting sales prices and volumes in the pharmaceutical industry[15]. - The group experienced a pre-tax loss of approximately RMB 2,122.8 million, a significant decline from a profit of RMB 496.0 million in the previous year[15]. - The net loss attributable to the company’s owners for the year was RMB 1,914,918 thousand, compared to a profit of RMB 416,509 thousand in 2021[35]. - The company reported a significant increase in other expenses, totaling RMB 936,581 thousand in 2022 compared to RMB 868,069 thousand in 2021[34]. Revenue Segmentation - The aesthetic medicine segment's revenue was approximately RMB 149.8 million, a decline of 62.5% from RMB 399.0 million in the previous year[3]. - Revenue from the innovative drugs and other pharmaceuticals segment increased by 47.5% to approximately RMB 60.9 million, compared to RMB 41.3 million in the previous year[3]. - The generics segment reported revenue of approximately RMB 1,970.5 million, down from RMB 2,598.1 million, with an operating loss of approximately RMB 16.0 million[3]. - The medical beauty products segment generated external customer sales of RMB 149,780 thousand in 2022, down from RMB 398,954 thousand in 2021, reflecting a decrease of about 62.5%[52]. - The innovative drugs and other pharmaceuticals segment reported external sales of RMB 60,913 thousand in 2022, compared to RMB 41,296 thousand in 2021, indicating an increase of approximately 47.9%[52]. - The generic drugs segment achieved external sales of RMB 1,970,496 thousand in 2022, down from RMB 2,598,141 thousand in 2021, a decline of around 24.1%[52]. Research and Development - Research and development expenses for the year were approximately RMB 936.6 million, an increase of RMB 68.5 million from RMB 868.1 million in the previous year[3]. - The company reported an operating loss of RMB 1,400.2 million in its innovative drug and other business segments, with R&D expenses rising by 21.3% to RMB 722.7 million compared to the previous year[20]. - XuanZhu Biotech has made significant progress in the development of multiple products, with nearly 10 products approved for clinical trials and over a dozen candidate drugs in preclinical development[11]. - The clinical trial for the first-line treatment of Birociclib (XZP-3287) in combination with aromatase inhibitors is currently in Phase III, showing potential for Best-in-class status[22]. - The IND application for KM501, a bispecific antibody-drug conjugate targeting HER2, has been accepted, marking it as the first patented bispecific ADC in China[22]. Strategic Focus and Transformation - The company has successfully transitioned towards innovative drug development, shedding underperforming generic drug segments, and has been recognized as a "Pioneer in Transformation" in the Greater China region[8]. - The company is focusing on high-growth and high-margin sectors, optimizing its operations by gradually divesting from underperforming generic drug businesses[8]. - The company is transitioning its CDMO business focus away from being a core area, with plans to divest non-core pharmaceutical assets[13]. - The company aims to accelerate its dual-driven strategy in 2023, concentrating on high-growth medical aesthetics and innovative drug sectors while optimizing its generic drug business[32]. - The strategic focus will shift towards high-value innovative drugs and biopharmaceuticals, ensuring rapid advancement of research pipelines and product launches[32]. Financial Position and Cash Flow - As of December 31, 2022, the group's cash and cash equivalents, along with financial products, amounted to approximately RMB 4,791.9 million[5]. - The company's cash and cash equivalents as of December 31, 2022, were RMB 3,828.9 million, a decrease from RMB 5,682.4 million in 2021[153]. - The debt-to-equity ratio was 25.1%, indicating a stable financial position[151]. - Cash flow from operating activities was RMB 46,493 thousand, significantly lower than RMB 665,293 thousand in the previous year[40]. - The company incurred cash outflows of RMB 1,661,121 thousand from investing activities, compared to RMB 337,569 thousand in the prior year[40]. Market and Industry Outlook - The global GDP growth rate is projected to decline from 6.0% in 2021 to 3.2% in 2022, and further to 2.7% in 2023 according to the International Monetary Fund[6]. - The medical beauty industry faced challenges in 2022 due to repeated COVID-19 lockdowns, but is expected to experience a "V" shaped recovery in 2023 as demand rebounds[6]. - The pharmaceutical industry saw significant volatility in 2022, with the implementation of price reductions impacting profit margins, but is anticipated to improve as domestic pandemic policies are optimized[7]. Corporate Governance and Compliance - The financial statements have been prepared in accordance with International Financial Reporting Standards and presented in RMB[44]. - The company complied with all applicable corporate governance codes during the reporting period[174]. - The audit committee reviewed the group's financial reporting and internal control systems for the year ended December 31, 2022[176]. - The company plans to amend its rules to comply with the revised listing rules and Bermuda applicable laws, ensuring shareholder protection through a unified set of 14 "core standards" starting from January 1, 2022[183].

Share Incentive Plan Adoption - The board announced the adoption of the 2022 Share Incentive Plan on October 25, 2022[2]. - The plan was adopted on October 25, 2022, and is governed by the company's organizational bylaws[17]. Securities and Issuance - The total number of securities available for issuance under the plan is 98,776,000 shares, representing approximately 1.06% of the issued shares[2]. - The total number of shares that can be granted under the plan shall not exceed 3% of the company's issued share capital, approximately 250 million shares[7]. - The total number of securities available for issuance under the 2021 share option plan is 98,776,000 shares, accounting for approximately 1.06% of the issued shares[16]. Plan Duration and Termination - The plan will be effective for a period of ten years from the adoption date, unless terminated earlier by the board[4]. - The plan may be terminated by the board of directors, and unvested rewards will immediately become void under certain circumstances, such as regulatory penalties[15]. Granting and Vesting Conditions - Individual grants to participants in any 12-month period shall not exceed 1% of the company's issued share capital[7]. - The rewards under the plan will vest in three equal tranches of 33.33% each, with the first tranche vesting on the first vesting date[12]. - Unvested rewards will automatically expire and be forfeited if certain conditions are not met, including the performance targets set forth in the reward agreement[12]. - The management has the discretion to determine the vesting conditions and may adjust the vesting schedule based on applicable laws[12]. - The plan is subject to adjustments based on the company's performance targets and the performance targets of the participants[12]. Participants and Eligibility - Eligible participants include directors, senior and middle management, and other qualified personnel[6]. - Any rewards granted to directors or major shareholders must be approved by independent non-executive directors[11]. Share Issuance and Rights - The company will not issue new shares for the rewards under the plan, but will purchase existing shares on the stock exchange[9]. - Shareholders' rights, including voting rights and dividend rights, are not conferred upon participants until the rewards are vested and shares are actually transferred[14]. - The management can instruct the trustee to transfer vested shares to the participants or their legal representatives upon the participant's death[13]. Board Approval and Management Discretion - The board will regularly approve grant plans, including the range of shares to be granted and the criteria for selecting participants[10]. - The plan does not involve the issuance of new shares or the granting of options for new securities, thus it does not constitute a share option plan regulated under Chapter 17 of the Listing Rules[16].

Financial Performance - Sihuan Pharmaceutical reported a significant increase in revenue, achieving a total of HKD 1.2 billion for the first half of 2022, representing a year-on-year growth of 15%[6]. - The company’s net profit for the same period was HKD 300 million, reflecting a 10% increase compared to the previous year[6]. - Sihuan Pharmaceutical recorded total revenue of approximately RMB1,464.2 million, a year-on-year decrease of 23.2% compared to RMB1,907.2 million in the same period of 2021, primarily due to the impact of the domestic epidemic[27]. - The medical aesthetic business segment achieved revenue of approximately RMB98.6 million, representing a year-on-year decrease of 61.8% due to reduced consumption from service interruptions caused by the epidemic[27]. - The generic drug business segment generated revenue of approximately RMB1,233.0 million, down 18.3% year-on-year, influenced by the ongoing domestic epidemic and pharmaceutical policy changes[27]. - Operating profit for the period was approximately RMB203.2 million, a significant decrease of 77.1% from RMB886.0 million in the same period of 2021[27]. - Profit before tax for the Period was approximately RMB56.0 million, significantly down from RMB819.5 million in the same period last year[95]. - The Group's loss for the Period amounted to approximately RMB95.9 million, compared to a profit of RMB594.2 million in the same period last year[99]. - Gross profit for the Period amounted to approximately RMB1,003.7 million, down from RMB1,467.1 million, resulting in a gross profit margin decrease from 76.9% to 68.5%[94]. Research and Development - Sihuan Pharmaceutical is investing HKD 200 million in R&D for new biopharmaceutical products, focusing on innovative therapies[6]. - Total R&D expenses amounted to approximately RMB457.3 million, reflecting a 37.1% increase compared to RMB333.6 million in the same period of 2021, aimed at developing over 100 medical aesthetic and biopharmaceutical products[27]. - R&D expenses for innovative drugs and other segments reached RMB317.5 million, an increase of 46.0% compared to the previous period[48]. - The Group's R&D and registration efforts led to the approval of nearly 20 Class II skin care dressing products and the hyaluronic acid product Persnica® by the National Medical Products Administration[20]. - Xuanzhu Biopharm has over 25 innovative drugs under development, focusing on oncology, metabolism, and digestion[23]. - The phase III clinical trials for Birociclib, a CDK4/6 inhibitor, are currently ongoing for both second-line treatment with Fulvestrant and first-line treatment with AI[23]. - The New Drug Application (NDA) for Anaprazole Sodium for the treatment of peptic ulcer has been accepted by the NMPA, and phase II clinical trials for reflux esophagitis in adults have been approved[23]. - The IND application for AXL inhibitor XZB-0004 has been approved for clinical trials in advanced solid tumors and hematologic malignancies, with potential for combination therapies[56]. Market Strategy and Expansion - The company has set a target to achieve a revenue growth of 20% for the full year 2022, driven by new product launches and market expansion strategies[6]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[6]. - The Group plans to dispose of non-core pharmaceutical assets to concentrate resources on higher growth sectors, enhancing shareholder value and financial performance[18][19]. - The Group's strategic focus on innovative transformation in medical aesthetics and biopharmaceuticals has positioned it for growth amid market changes[18]. - The Group's proactive layout in medical aesthetics and biopharmaceuticals since 2012 has facilitated its transformation and development during market changes[18]. Impact of External Factors - The global economy faced multiple negative factors in the first half of 2022, including high inflation and liquidity tightening, which affected market performance[15]. - The pharmaceutical industry experienced varying degrees of impact due to COVID-19, with a significant decline in hospital medical services and a 48% average price reduction in the seventh batch of centralized procurement[17][18]. - The overall performance of the pharmaceutical industry was under pressure in the first half of 2022, particularly in areas severely affected by COVID-19[17]. Corporate Governance and Financial Position - The Group's debt to capital ratio remained low at 16.5%, indicating a strong financial position[31]. - As of June 30, 2022, the Group's cash and cash equivalents plus wealth management products totaled approximately RMB5,246.0 million, with a net amount of approximately RMB4,049.0 million after deducting interest-bearing borrowings[31]. - The Group's bank borrowings increased to approximately RMB1,120.2 million from RMB1,013.2 million at the end of 2021[102]. - The Group's employee bonuses for the period were approximately RMB14.2 million, compared to RMB9.4 million in the same period of 2021[132]. - The Group has adopted share option and share award schemes to recognize and reward employee contributions, promoting sustainable growth[131]. Product Development and Innovation - A new line of medical aesthetic products is expected to launch in Q4 2022, projected to contribute an additional HKD 100 million in revenue[6]. - The Group's focus on a "Product First" principle has led to the continuous development of its medical aesthetic product matrix, including minimally invasive solutions[39]. - The Group's exclusive product, Persnica®, a modified sodium hyaluronate gel, received Class III medical device certification from the NMPA in April 2022, indicating its compliance with regulatory standards[40]. - The Group introduced the Sylfirm XTM golden microneedle product from VIOL Co., Ltd and acquired 60% equity interest in Shenzhen Yimei Medical Technology during the period[20]. Shareholder Information - Dr. Che Fengsheng holds a total of 5,133,125,704 shares, representing approximately 55.02% of the shareholding[135]. - The company has a total of 5,133,125,704 shares outstanding, with a significant shareholder, Network Victory Limited, holding approximately 55.02% of the shares[147]. - The total number of shares held by major shareholders is recorded in the company's register, indicating significant ownership concentrations[146]. - The Company declared an interim cash dividend of RMB0.1 cents per share and a special cash dividend of RMB3.2 cents per share, payable on or around October 13, 2022[183].